Published in MAbs on January 01, 2014
High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science (2007) 20.32
The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Science (2008) 11.74
Seven-transmembrane receptors. Nat Rev Mol Cell Biol (2002) 11.50
Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science (2010) 10.30
The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Mol Pharmacol (2003) 9.99
G-protein-coupled receptors and cancer. Nat Rev Cancer (2007) 6.80
Structural diversity of G protein-coupled receptors and significance for drug discovery. Nat Rev Drug Discov (2008) 6.18
A novel peptide CXCR ligand derived from extracellular matrix degradation during airway inflammation. Nat Med (2006) 5.05
Quantification of CD4, CCR5, and CXCR4 levels on lymphocyte subsets, dendritic cells, and differentially conditioned monocyte-derived macrophages. Proc Natl Acad Sci U S A (1999) 4.61
Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library. Nat Biotechnol (1996) 4.45
Structure of the δ-opioid receptor bound to naltrindole. Nature (2012) 3.69
The G protein-coupled receptor repertoires of human and mouse. Proc Natl Acad Sci U S A (2003) 3.24
Critical role for CXCR2 and CXCR2 ligands during the pathogenesis of ventilator-induced lung injury. J Clin Invest (2002) 3.08
Depletion of CXCR2 inhibits tumor growth and angiogenesis in a murine model of lung cancer. J Immunol (2004) 2.34
Structure determination of the seven-helix transmembrane receptor sensory rhodopsin II by solution NMR spectroscopy. Nat Struct Mol Biol (2010) 2.17
The 7 TM G-protein-coupled receptor target family. ChemMedChem (2006) 2.00
HBTU activation for automated Fmoc solid-phase peptide synthesis. Pept Res (1992) 1.91
Nonapical and cytoplasmic expression of interleukin-8, CXCR1, and CXCR2 correlates with cell proliferation and microvessel density in prostate cancer. Clin Cancer Res (2005) 1.90
High expression of ligands for chemokine receptor CXCR2 in alveolar epithelial neoplasia induced by oncogenic kras. Cancer Res (2006) 1.84
Proteolytic selection for protein folding using filamentous bacteriophages. Fold Des (1998) 1.69
A growth-related oncogene/CXC chemokine receptor 2 autocrine loop contributes to cellular proliferation in esophageal cancer. Cancer Res (2006) 1.66
The myocardium-protective Gly-49 variant of the beta 1-adrenergic receptor exhibits constitutive activity and increased desensitization and down-regulation. J Biol Chem (2002) 1.63
Modelling the human immune response: performance of a 1011 human antibody repertoire against a broad panel of therapeutically relevant antigens. Protein Eng Des Sel (2008) 1.45
CXCR2 promotes ovarian cancer growth through dysregulated cell cycle, diminished apoptosis, and enhanced angiogenesis. Clin Cancer Res (2010) 1.42
Rapid and quantitative cyclization of multiple peptide loops onto synthetic scaffolds for structural mimicry of protein surfaces. Chembiochem (2005) 1.42
Therapeutic antibodies directed at G protein-coupled receptors. MAbs (2010) 1.41
Blockade of the chemokine receptor CXCR2 inhibits pancreatic cancer cell-induced angiogenesis. Cancer Lett (2006) 1.41
Sialylated O-glycans and sulfated tyrosines in the NH2-terminal domain of CC chemokine receptor 5 contribute to high affinity binding of chemokines. J Exp Med (2001) 1.39
Conformation state-sensitive antibodies to G-protein-coupled receptors. J Biol Chem (2006) 1.37
Effect of posttranslational processing on the in vitro and in vivo activity of chemokines. Exp Cell Res (2010) 1.27
CXC-chemokine/CXCR2 biological axis promotes angiogenesis in vitro and in vivo in pancreatic cancer. Int J Cancer (2009) 1.25
Functional reconstruction and synthetic mimicry of a conformational epitope using CLIPS technology. J Mol Recognit (2007) 1.21
Structural aspects of antibody-antigen interaction revealed through small random peptide libraries. Mol Divers (1996) 1.20
Post-translational control of chemokines: a role for decoy receptors? Immunol Lett (2005) 1.03
CXC chemokine receptor 2 contributes to host defense in murine urinary tract infection. J Infect Dis (2001) 0.99
Interleukin 8, neutrophil-activating peptide-2 and GRO-alpha bind to and elicit cell activation via specific and different amino acid residues of CXCR2. Cytokine (2000) 0.98
Mutations in the extracellular amino-terminal domain of the NK2 neurokinin receptor abolish cAMP signaling but preserve intracellular calcium responses. J Biol Chem (2002) 0.94
Molecular characterization of receptors for human interleukin-8, GRO/melanoma growth-stimulatory activity and neutrophil activating peptide-2. Mol Immunol (1993) 0.94
Effects of immunization with CCR5-based cycloimmunogen on simian/HIVSF162P3 challenge. J Immunol (2006) 0.93
Selection of active ScFv to G-protein-coupled receptor CCR5 using surface antigen-mimicking peptides. Biochemistry (2004) 0.93
Affinity maturation of phage display antibody populations using ribosome display. J Immunol Methods (2006) 0.90
Contrasting roles for CXCR2 during experimental colitis. Exp Mol Pathol (2004) 0.90
Production and characterization of highly tumor-specific rat monoclonal antibodies recognizing the extracellular domain of human L-type amino-acid transporter 1. Cancer Sci (2008) 0.86
Strategies for designing GPCR-focused libraries and screening sets. Curr Opin Drug Discov Devel (2004) 0.85
G-protein-directed ligand discovery with peptide combinatorial libraries. Trends Biochem Sci (2005) 0.84
Chimeric strategies for the rational design of bioactive analogs of small peptide hormones. FASEB J (1997) 0.84
Depletion of CXCR2 inhibits γ-secretase activity and amyloid-β production in a murine model of Alzheimer's disease. Cytokine (2010) 0.82
Ligand identification for G-protein-coupled receptors: a lead generation perspective. Curr Opin Chem Biol (2004) 0.80
Identification of biologically active peptides that inhibit binding of human CXCL8 to its receptors from a random phage-epitope library. J Leukoc Biol (2008) 0.78
The E3 SUMO ligase PIASy is a regulator of cellular senescence and apoptosis. Mol Cell (2006) 1.90
IKKi/IKKepsilon plays a key role in integrating signals induced by pro-inflammatory stimuli. J Biol Chem (2003) 1.38
PARP-1 transcriptional activity is regulated by sumoylation upon heat shock. EMBO J (2009) 1.33
Induction of the NF-kappaB cascade by recruitment of the scaffold molecule NEMO to the T cell receptor. Immunity (2003) 1.18
Isoforms of alanine aminotransferases in human tissues and serum--differential tissue expression using novel antibodies. Arch Biochem Biophys (2007) 1.10
Wnt/β-catenin signaling requires interaction of the Dishevelled DEP domain and C terminus with a discontinuous motif in Frizzled. Proc Natl Acad Sci U S A (2012) 1.07
Acute pharmacodynamic and antivascular effects of the vascular endothelial growth factor signaling inhibitor AZD2171 in Calu-6 human lung tumor xenografts. Mol Cancer Ther (2007) 1.06
Mapping of a discontinuous and highly conformational binding site on follicle stimulating hormone subunit-beta (FSH-beta) using domain Scan and Matrix Scan technology. Mol Divers (2004) 0.96
Spatial interplay between PIASy and FIP200 in the regulation of signal transduction and transcriptional activity. Mol Cell Biol (2008) 0.95
Validation of the BRCA1 antibody MS110 and the utility of BRCA1 as a patient selection biomarker in immunohistochemical analysis of breast and ovarian tumours. Virchows Arch (2013) 0.84
A peptide mimic of an antigenic loop of alpha-human chorionic gonadotropin hormone: solution structure and interaction with a llama V(HH) domain. Biochem J (2002) 0.78
Antibody recognition of a human chorionic gonadotropin epitope (hCGbeta66-80) depends on local structure retained in the free peptide. J Biol Chem (2011) 0.77
Therapeutic modulation of inflammatory gene transcription by kinase inhibitors. Expert Opin Biol Ther (2002) 0.76
Characterization of the complex formed between a potent neutralizing ovine-derived polyclonal anti-TNFα Fab fragment and human TNFα. Biosci Rep (2013) 0.76